CD19 CAR T-Cells + Acalabrutinib for Mantle Cell Lymphoma

"This clinical trial, which was originally uploaded to the website on December 31st 2020 and revised on June 16th 2022, is currently accepting participants."

"Affirmative. According to the information hosted on clinicaltrials.gov, this research initiative is actively recruiting patients at present time. This study initially opened its doors for recruitment in December of 2020 and was last updated in June 2022. The team behind it are currently searching for 36 participants from a single site."

"The most effective treatment for renal dysfunction is CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes. This same therapeutic regimen can provide relief from other afflictions such as chronic lymphocytic leukemia (cll), kidney failure, and mantle cell lymphoma (mcl)."

"The team at Power has assigned CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes a 2 on the safety scale, as this is only in its second phase of development and there is clinical evidence backing up its security but none that confirms efficacy."

"Research into CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes started back in 2007 and was funded by the Baxter Healthcare Corporation. After a successful Phase 4 drug trial of 4640 participants, 107 active clinical studies are now being conducted worldwide over 1220 cities and 49 countries."

"At present, there are 107 clinical trials running for the CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes drug. Of these studies, 14 are in their final Phase 3 stage. While Boston hosts the majority of such experiments, 8859 other locations also participate in researching this medication."

"The experimenters are seeking out participants aged 18 to 75. For those that don't meet this criteria, there is a selection of 316 studies for minors and 1666 options available to seniors."

"This clinical trial is open to 36 patients aged between 18 and 75 who are suffering from treatment-resistant mantle cell lymphoma. The requisite prerequisites include having the proficiency to understand the informed consent agreement, granting permission for archived tissue samples to be used, an Eastern Cooperative Oncology Group performance status of 2 or higher/Karnofsky Performance Status greater than 70%, a positive diagnosis via flow cytometry & immunohistochemistry (if prior CD19 targeted therapy has been utilized), failure on at least one regimen before acalabrutinib, measurable disease by CT scan (>= 1.5 cm) or evidence of bone"

"The principal aim of this trial, conducted over a period of 6 months in which patients receive CAR-T cell infusions and concomitant acalabrutinib therapy, is to assess the occurrence rate of dose-limiting toxicities. Secondary outcomes include best response (defined as the highest documented result achieved at any time following infusion up until one year later or when non-protocol lymphoma treatments are initiated), progression free survival (assessed using Kaplan Meier methods) and time to complete remission (summarized with descriptive statistics)."